# Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors

> **NCT07675070** · — · RECRUITING · sponsor: **NanoAlvand** · enrollment: 100 (estimated)

## Conditions studied

- Brain Tumor
- Grade III Glioma
- Grade IV Glioma

## Interventions

- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT07675070
- **Lead sponsor:** NanoAlvand
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-22
- **Primary completion:** 2026-09
- **Final completion:** 2026-11
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07675070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07675070, "Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07675070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*